US 12,324,809 B2
Fluoro beta-carboline compounds
Debra Ellies, Parkville, MO (US); F. Scott Kimball, Olathe, KS (US); and Robert N. Young, Vancouver (CA)
Assigned to OSSIFI THERAPEUTICS LLC, Overland Park, KS (US)
Filed by OSSIFI THERAPEUTICS LLC, Overland Park, KS (US)
Filed on Jan. 17, 2024, as Appl. No. 18/415,359.
Application 18/415,359 is a division of application No. 16/539,894, filed on Aug. 13, 2019, granted, now 11,903,949.
Claims priority of provisional application 62/718,604, filed on Aug. 14, 2018.
Prior Publication US 2025/0025472 A1, Jan. 23, 2025
Int. Cl. A61K 31/5377 (2006.01); A61K 31/444 (2006.01); A61K 31/496 (2006.01); A61K 31/5386 (2006.01); A61K 31/55 (2006.01); A61K 35/32 (2015.01); A61K 39/395 (2006.01); A61P 19/10 (2006.01); C07D 471/04 (2006.01); C07D 491/048 (2006.01); C07D 498/08 (2006.01)
CPC A61K 31/5377 (2013.01) [A61K 31/444 (2013.01); A61K 31/496 (2013.01); A61K 31/5386 (2013.01); A61K 31/55 (2013.01); A61K 35/32 (2013.01); A61K 39/3955 (2013.01); A61P 19/10 (2018.01); C07D 471/04 (2013.01); C07D 491/048 (2013.01); C07D 498/08 (2013.01)] 20 Claims
 
1. A method of promoting bone formation of a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, hydrate or prodrug thereof,
thereby promoting bone formation in the subject.